4-Methyl-5-phenyl-1,2,3-thiadiazol | 18212-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methyl-5-phenyl-1,2,3-thiadiazol
• 英文别名: 4-Methyl-5-phenyl-1,2,3-thiadiazole；4-methyl-5-phenylthiadiazole
• CAS: 18212-30-1
• 化学式: C₉H₈N₂S
• mdl: MFCD18449419
• 分子量: 176.242
• InChiKey: NTNMHLKGQUQMPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Methyl-5-phenyl-1,2,3-thiadiazol 以 二氯甲烷 为溶剂， 520.0~530.0 ℃ 、0.13 Pa 条件下， 生成 Methylphenylthioketen
  参考文献：
  名称：

  Schaumann,E. et al., Liebigs Annalen der Chemie, 1979, p. 1734 - 1745

  摘要：

  DOI：
• 作为产物：
  描述：

  phenethylidene-hydrazinecarboxylic acid methyl ester 在 氯化亚砜 作用下， 生成 4-Methyl-5-phenyl-1,2,3-thiadiazol
  参考文献：
  名称：

  1,2,3-噻二唑与碱反应。I. 1-炔基硫醚的新路线

  摘要：

  5-位未取代的 1,2,3-噻二唑与强碱（如有机锂化合物、钠酰胺、甲基亚磺酰基碳负离子钠或叔丁醇钾）之间的反应导致噻二唑环系统裂解，并产生氮和碱金属炔硫醇盐的形成。随后向反应混合物中加入烷基卤或酰基卤产生1-炔基硫醚。4-(5-苯基-1,2,3-噻二唑基)锂，由5-苯基-1,2,3-噻二唑和甲基-或苯基锂得到，与甲基碘反应生成4-甲基-5-苯基- 1,2,3-噻二唑。

  DOI：

  10.1139/v68-179

文献信息

• Reactions of Lithiated 1,2,3-Thiadiazoles: Synthesis of 4-Substituted 1,2,3-Thiadiazoles
  作者：Edward W. Thomas、David C. Zimmermann

  DOI：10.1055/s-1985-31395

  日期：——

  Metalation of 5-phenyl-1,2,3-thiadiazole (2) with methyllithium affords 4-lithio-5-phenyl-1,2,3-thiadiazole, which is stable and reacts with aldehydes and ketones to give 4-substituted 1,2,3-thiadiazoles 3 in excellent yields. Treatment of 4-phenyl-1,2,3-thiadiazole (1) with lithium diisopropylamide, in the presence of chlorotrimethylsilane, affords 4-phenyl-5-trimethylsilyl-1,2,3-thiadiazole (7).

  将5-苯基-1,2,3-噻二唑（2）与甲基锂金属化反应，生成稳定的4-锂-5-苯基-1,2,3-噻二唑，该化合物能与醛和酮反应，以优异的产率得到4-取代的1,2,3-噻二唑（3）。在三甲基氯硅烷的存在下，用二异丙基氨基锂处理4-苯基-1,2,3-噻二唑（1），得到4-苯基-5-三甲基硅基-1,2,3-噻二唑（7）。
• Lithiation of five-membered heteroaromatic compounds. The methyl substituted 1,2-azoles, oxadiazoles, and thiadiazoles
  作者：R. G. Micetich

  DOI：10.1139/v70-334

  日期：1970.7.1

  The lithiation of various methyl substituted isoxazoles, isothiazoles, pyrazoles, oxadiazoles, and thiadiazoles using n-butyllithium has been studied. Three types of reactions, namely, lateral lithiation, ring cleavage, and addition of butyllithium to the ring, have been found. 3,5-Dimethylisoxazole, 3-phenyl-5-methylisoxazole, 3,4-dimethyl-1,2,5-oxadiazole, 2,5-dimethyl-1,3,4-thiadiazole, 3-phenyl-5-methyl-1,2,4-oxadiazole, and 3,5-dimethyl-1,2,4-thiadiazole all undergo lateral lithiation to give the respective acetic acids after carboxylation. 1-Methyl-3,5-disubstituted pyrazoles form the 1-lithiomethyl derivatives, while 1-phenyl-3,5-disubstituted pyrazoles are converted to the 1-ortholithiophenyl-3,5-disubstituted pyrazoles. 4-Methylisothiazole is lithiated mainly at C-5, but also suffers ring cleavage to form 1-n-butylthio-2-cyanoprop-1-ene. Heteroaromatic compounds containing an N—S bond, such as 3,4-dimeth yl-1,2,5-thiadiazole, 4-methyl-5-phenyl-1,2,3-thiadiazole, and 3,5-dimethylisothiazole, undergo nucleophilic attack at sulfur with resulting ring cleavage. 3,5-Dimethylisothiazole produces 2-n-butylthiopent-2-en-4-one. 3-Methyl-5-phenyl-1,2,4-oxadiazole gave 3-methyl-5-phenyl-5-n-butyl-1,2,4-dihydroöxadiazole by addition to the azomethine bond. The results of these lithiations are discussed. 3-Methyl-5-lithiomethylisoxazole was converted to various derivatives. Nuclear magnetic resonance spectral analysis was used to establish the identity of the products.

  各种甲基取代异噁唑、异硫唑、吡唑、噁二唑和噻二唑的锂化反应已经被研究。发现了三种类型的反应，即侧链锂化、环裂解和丁基锂加入环中。3,5-二甲基异噁唑、3-苯基-5-甲基异噁唑、3,4-二甲基-1,2,5-噁二唑、2,5-二甲基-1,3,4-噻二唑、3-苯基-5-甲基-1,2,4-噁二唑和3,5-二甲基-1,2,4-噻二唑都经历侧链锂化，在羧化后生成相应的乙酸。1-甲基-3,5-二取代吡唑形成1-锂甲基衍生物，而1-苯基-3,5-二取代吡唑转化为1-邻锂苯基-3,5-二取代吡唑。4-甲基异硫唑主要在C-5处发生锂化，但也发生环裂解形成1-正丁硫基-2-氰基丙-1-烯。含有N—S键的杂环化合物，如3,4-二甲基-1,2,5-噻二唑、4-甲基-5-苯基-1,2,3-噻二唑和3,5-二甲基异硫唑，在硫原子上发生亲核攻击，导致环裂解。3,5-二甲基异硫唑产生2-正丁硫代戊-2-烯-4-酮。3-甲基-5-苯基-1,2,4-噁二唑通过加成到偶氮亚胺键生成3-甲基-5-苯基-5-正丁基-1,2,4-二氢噁二唑。讨论了这些锂化的结果。3-甲基-5-锂甲基异噁唑被转化为各种衍生物。核磁共振光谱分析用于确定产物的身份。
• INHIBITORS OF IAP
  申请人：Ndubaku Chudi

  公开号：US20110046066A1

  公开（公告）日：2011-02-24

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 4 ′, R 5 , R a , R b , and R c are as described herein.

  这项发明提供了新型IAP抑制剂，可作为治疗剂用于治疗恶性肿瘤，其中化合物具有一般式(I)，并且G、X1、X2、R1、R2、R3、R4、R4'、R5、Ra、Rb和Rc如本文所述。
• Inhibitors of IAP
  申请人：Cohen Frederick

  公开号：US20070299052A1

  公开（公告）日：2007-12-27

  The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R 1 , R 2 , R 3 , R 4 , R 4 ′, R 5 , R 5 ′, R 6 and R 6 ′ are as described herein.

  该发明提供了新型的IAP抑制剂，可用作治疗恶性肿瘤的治疗剂，其中化合物具有一般式I，其中X、Y、A、R1、R2、R3、R4、R4'、R5、R5'、R6和R6'如本文所述。
• IAP BINDING COMPOUNDS
  申请人：Lundorf Mikkel Dybro

  公开号：US20110230419A1

  公开（公告）日：2011-09-22

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, that bind to Inhibitor of Apoptosis Proteins (IAPs). The compounds of the invention may be used as diagnostic and therapeutic agents in the treatment of proliferative diseases, such as cancer, for promoting apoptosis in proliferating cells, and for sensitizing cells to inducers of apoptosis. The present invention furthermore provides a polymeric compound of formulas (VI) or (VII), comprising either at least two monomeric units of compounds of formula (I), or at least one monomeric unit of a compound of formula (I) and an entity E. The present invention further relates to pharmaceutical compositions comprising said compounds of formulas (I), (VI), and (VII) and the use of said compounds in medicine.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂化合物或前药，其与凋亡抑制蛋白（IAPs）结合。本发明的化合物可用作诊断和治疗增生性疾病，例如癌症，促进增殖细胞的凋亡，并使细胞对凋亡诱导剂敏感。本发明还提供式(VI)或(VII)的聚合物化合物，其中包括至少两个式(I)的单体单位，或至少一个式(I)的单体单位和一个实体E。本发明还涉及包含上述化合物的药物组合物，以及在医学中使用上述化合物的用途。